drugset / Trial / NCT00448149
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
Phase 1/2
Completed
55 enrolled
The Methodist Hospital Research Institute
Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see whether the combination for RAD001 and Nexavar® works better when given together than they do alone. The purpose of the first phase of this study is to determine the best dose of RAD001 given with Nexavar®, and to see what effects, good and/or bad, the study drug has on the subject and the subject's tumor. This study will also observe side effects experienced by the subject.
Timeline
- Start
- 2006-12
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 2.5 mg | Oral |
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |